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Article

Generation of a stable packaging cell line producing high-titer
PPT-deleted integration-deficient lentiviral vectors
Peirong Hu1,2, Yedda Li3, Mark S Sands3,4, Thomas McCown1,5 and Tal Kafri1,2

The risk of insertional mutagenesis inherent to all integrating exogenous expression cassettes was the impetus for the development of various integration-defective lentiviral vector (IDLV) systems. These systems were successfully employed in a plethora
of preclinical applications, underscoring their clinical potential. However, current production of IDLVs by transient plasmid
transfection is not optimal for large-scale production of clinical grade vectors. Here, we describe the development of the first
tetracycline-inducible stable IDLV packaging cell line comprising the D64E integrase mutant and the VSV-G envelope protein.
A conditional self-inactivating (cSIN) vector and a novel polypurine tract (PPT)-deleted vector were incorporated into the newly
developed stable packaging cell line by transduction and stable transfection, respectively. High-titer (~107 infectious units (IU)/ml)
cSIN vectors were routinely generated. Furthermore, screening of single-cell clones stably transfected with PPT-deleted vector
DNA resulted in the identification of highly efficient producer cell lines generating IDLV titers higher than 108 IU/mL, which upon
concentration increased to 1010 IU/ml. IDLVs generated by stable producer lines efficiently transduce CNS tissues of rodents. Overall,
the availability of high-titer IDLV lentivirus packaging cell line described here will significantly facilitate IDLV-based basic science
research, as well as preclinical and clinical applications.
Molecular Therapy — Methods & Clinical Development (2015) 2, 15025; doi:10.1038/mtm.2015.25; published online 22 July 2015

INTRODUCTION
The recent successes of integration-competent lentiviral vectors
(ICLVs) targeting patients’ hematopoietic stem cells (HSC) in altering the pathologic course of fatal genetic diseases have opened a
new avenue in treating incurable diseases.1–4 However, the prospect
of broadening the usage of the above therapeutic methodology to
include nonfatal diseases is limited by the risk of insertional mutagenesis inherent to all integrating vectors. Indeed, data accumulated
from various preclinical studies have raised major concerns regarding
the oncogenic potential of gamma-retroviral and lentiviral vectors.5–10
These concerns have materialized in several human clinical trials in
which autologous bone marrow transplantation of gamma-retroviral
vector-transduced HSC resulted in tumor development.11–13 Taking a
similar therapeutic approach, Cavazzana-Calvo et al.4 have successfully employed ICLV’s to deliver a β-globin gene expression cassette
to patients’ HSC as a means to treat β-thalassemia. However, reports
from this trial describe clonal expansion of the myeloid lineage due to
vector-mediated insertional mutagenesis, leading to dysregulation of
the HMGA2 gene in progenitor cells.
Biosafety concerns regarding ICLV-associated insertional mutagenesis and the desire to harness the advantages of lentiviral vectors—including low immunogenicity, high capacity, and the ability
to transduce nondividing cells—were the impetus for the development of integration-defective lentiviral vectors (IDLVs). Generally,

IDLVs are packaged into vector particles carrying class I integrase
mutants in which one amino acid in the DDE conserved catalytic
triad (predominantly the D64 residue) is mutated.14–21 Several studies have d
emonstrated different levels of illegitimate integraseindependent integration (up to one integration event per 200 vector
genomes).14,20,22–24 However, the development of the polypurine tract
(PPT)-deleted IDLVs by Kantor et al. has significantly reduced the levels of illegitimate integration.24,25
IDLVs have efficiently transduced a plethora of cell lines and
various primary cells including human embryo fibroblasts, human
macrophages, HSC, primary neuronal cells, and embryonic stem
cells.14,16,18–20,22,24,26–33 Different laboratories have demonstrated the
ability of IDLVs to maintain long-term expression of reporter genes
in non-dividing cells in various target organs, including the CNS, spinal cord, muscle, eye, and liver.14,16,18,20,27,31,34,35 Furthermore, Thrasher
et al. and Suwanmanee et al. have successfully employed IDLVs in
mouse models of gene replacement therapy for degenerative retinal disease and hemophilia B.35,36 The efficacy of IDLVs in cancer
immunotherapy and as a means of inducing protective immune
responses to human pathogens has been characterized in different
experimental settings.37–46 Importantly, a growing number of manuscripts have described IDLVs carrying either zinc-finger nucleases,
and the CRISPR-Cas 9 system as an effective means of gene editing
for clinical and basic science applications.47–52
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competent retroviruses (RCRs) were the drive for the establishment
of several stable ICLV packaging cell lines.57–62
Here, we describe the establishment of the first IDLV packaging
cell line, which generates high titer, VSV-G pseudotyped conditional
SIN and PPT-deleted IDLVs. The vectors efficiently transduce rodent
CNS. The novel packaging cell line will facilitate the scaling up in
production of safer IDLVs more suitable for clinical trials.

In the early stages of retroviral vector development, production
of gamma-retroviral vectors was premised on stable packaging cell
lines.53 The establishment of the highly transfectable 293T in the
early 90’s allowed Pear et al.54 to produce high-titer retroviral vectors by transient transfection. The ability to pseudotype retroviral
vectors with the VSV-G envelope further facilitated production of
high-titer retroviral vector particles.55 Premised on the aforementioned advancements in retroviral vector production, Naldini
et al.56 employed transient three-plasmid transfection to produce
and concentrate VSV-G pseudotyped lentiviral vector to transduce
murine neurons in vivo. Similar successes employing transient plasmid transfection in producing high-titer lentiviral vectors rendered
this approach most popular. Notwithstanding the ease of producing high-titer lentiviral vectors by transient transfection, the need
to scale up vector production, to reduce variability between vector preparations, and to reduce the risk of emerging replication

RESULTS
The establishment of the IDLV inducible stable packaging cell line
Maximizing vector biosafety and titers are the main guidelines to be
followed in establishing all lentiviral viral vector stable packaging
cell lines. Encouraged by earlier studies of VSV-G pseudotyped lentiviral vectors demonstrating efficient transduction of brain and liver
tissues in vivo and HSC ex vivo, we based the first IDLV packaging
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Figure 1 Schematic outline for generating tetracycline-regulated integration-defective lentiviral vector packaging system. The PVG3 cell line
constitutively expresses the synthetic tetracycline-regulated trans activator tTA under the control of a cytomegalovirus promoter, as well as the VSV-G
envelope protein and the green fluorescent protein (GFP) marker gene from a bidirectional tetracycline-regulated expression cassette (depicted by a
bidirectional arrow). Packaging cell lines were generated by stably transfecting PVG3 cells with the tetracycline-regulated HIV-1 packaging construct
pTK1574, followed by G418 selection. p24gag enzyme-linked immunosorbent assay was used to identify and screen for high levels of particle production
in cell clones expressing minimal—yet detectable—levels of GFP (in the presence of doxycycline (Dox)). Producer cell lines were further established
by either transduction or stable transfection.
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cell line on this highly effective and broadly used envelope protein.
To minimize the likelihood of emerging RCRs, we split the process
of incorporating the VSV-G envelope and the packaging expression
cassettes into the genome of the future packaging cells to two independent stable transfection procedures (Figure 1). To address the
potential hurdle associated with constitutive expression of the cytotoxic HIV-1 protease and the VSV-G envelope proteins,63–65 the aforementioned expression cassettes were placed under the control of
tetracycline-inducible promoters. The IDLV packaging construct
(pTK1574) was established by placing an HIV-1 packaging cassette
expressing the HIV-1 Gag, Pol, Tat, Rev, and Vpu under the control
of a tetracycline inducible promoter (Figure 2a). A D64E HIV-1 integrase mutant encoded by the above Pol gene renders the vector
particles generated by the novel inducible packaging cassette integration defective. The efficiency of the novel packaging system at
generating IDLVs in a tetracycline regulated fashion was evaluated
by transiently transfecting it along with a conventional HIV-1 vector
expressing the green fluorescent protein (GFP) under the control
of a cytomegalovirus (CMV) promoter16 (pTK945, Figure 2a) and a
VSV-G envelope expression cassette (pMDG) into SODk0 cells, either
in the presence or absence of doxycycline (dox). The SODk0 cell line
constitutively expresses the synthetic tetracycline regulated transactivator tTA.60 Physical and infectious titers of vector particles in
culture media at 72 hours post-transfection were determined by
p24gag enzyme-linked immunosorbent assay (ELISA) and by scoring

a

GFP expression following serial vector dilutions on 293T cells. In the
absence of dox, the novel packaging cassette supports efficient production of physical (p24gag 142.8 ng/ml) and infectious vector particles (1.42 ± 0.11 × 107 IU/ml). Per contra, addition of Dox to culture
media effectively inhibited vector production.
Encouraged by these results, we sought to stably transfect the
inducible IDLV packaging cassette into the human embryo kidney (HEK) 293-based PVG3 cell line, which was established in an
earlier study.58 The PVG3 cells constitutively express the synthetic
tetracycline-regulated trans activator tTA66 under the control of a
CMV promoter, as well as the VSV-G envelope protein and the GFP
marker gene from a bi-directional tetracycline-regulated expression
cassette (Figure 1). As shown in Figure 2b,c, VSV-G and GFP expression is tightly regulated in PVG3 cells. In the presence of Dox, PVG3
cells demonstrate a barely detectable VSV-G, and GFP expression.
However, Dox withdrawal and addition of sodium butyrate (SB), a
broad-spectrum histone deacetylase inhibitor resulted in robust
VSV-G and GFP expression (Figure 2b,c).
As a first step in establishing the stable IDLV producing cell line,
PVG3 cells were transfected with the inducible IDLV expression
cassette (pTK1574, Figures 1 and 2) and a total of 50 G418-resistant
cell clones were isolated and screened for minimal, yet detectable
GFP expression in the presence of 1 µg/ml Dox. A total of 15 GFP
expressing cell clones were identified, and p24gag ELISA was used
to determine their ability to produce high levels of vector particles
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Figure 2 Generating tetracycline highly regulated integration-defective lentiviral vector (IDLV) packaging cell lines. (a) Depiction of the tetracycline
inducible packaging vector pTK1574 containing the gag, pol (encoding the integrase-mutant D64E), vpu, rev, and tat genes under the control of
a tetracycline-regulated promoter and the HIV-1 vector pTK945 carrying the GFP marker gene under the control of a cytomegalovirus promoter.
(b) Tight regulation of the VSV-G envelope and the IDLV packaging cassettes in PVG3 cells and in the stable packaging cell lines 3–8 and 3–12. The
aforementioned cell lines were cultured either in presence of 1 µg/ml Dox or in the absence of Dox and in the presence of 5 mmol/l sodium butyrate.
Expression of HIV-1 Gag (p55 and p24), Pol (p66 and p51) and the VSV-G envelope proteins in the above cell lines in the presence and absence of Dox
were determined by western blot analysis. (c) Regulation of GFP expression in PVG3 and the packaging cell lines 3–8 and 3–12. The aforementioned
cell lines were cultured either in presence of 1 µg/ml Dox or in the absence of Dox and in the presence of 5 mmol/l sodium butyrate. Expression of GFP
was determined by fluorescence microscopy. Note that very weak expression of GFP could be detected in the presence of Dox.
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Table 1

Stable production of vector particles by packaging cell lines
P24gag (ng/ml)

Clone name
3–6

+Dox

-Dox day6

+SB day1

Beforea

N/Ac

335.78

415.40

After

N/A

358.01

N/A

817.59

b

3–8

Before
After

N/A

820.37

3–10

Before

N/A

629.42

After

N/A

635.27

3–12

Before

N/A

461.47

After

N/A

628.28

552.53
557.78
910.57

+SB day2

+SB day3

+SB day4

991.79

1,286.36

1,550.02

1,009.93

1,518.69

1,061.29

1,493.37

1,279.10

1,769.85

1,272.87

1,282.77

1,688.21

2,079.15

1,369.99

1,361.68

1,279.05

1,444.14

1,470.97
1,546.23
1,436.45

Vector particle production by four packaging cell lines before ( ) and after ( ) four passages in culture (in the absence of G418) was initiated by Dox withdrawal from
culture media. Sodium butyrate (SB, 5mM) was added to culture media after 6 days of induction. After 72 hours in conditioned media, vector particle concentration
was determined by p24gag ELISA. N/A (c) indicates p24gag measurement not higher than background.
b

upon Dox withdrawal and addition of SB. Interestingly, conditioned media obtained from the above 15 cell clones at 48 hours
postexposure to SB exhibited a wide range of p24gag concentrations, varying from undetectable levels up to 1,307.1 ng/ml. Next,
we characterized the kinetics of vector particle production upon
Dox withdrawal and addition of SB in the four cell clones exhibiting the highest p24gag levels (3–6, 3–8, 3–10, and 3–12). As shown
in Table 1, only moderate levels of p24gag were detected in conditioned media of the four cell clones at 6 days post-Dox withdrawal
(up to 817 ng/ml). However, all cell clones demonstrated a significant increase in vector particle production at 2 days post-SB addition, and maintained high concentrations of p24gag in conditioned
media up to 4 days postaddition of SB. However, increased cell
death and morphological changes were observed in the above
cell clones at 4 days post-SB exposure, indicating that between
2 to 3 days post-SB addition is the optimal time frame for vector
particles production.
Aware of the possibility that a residual expression of the HIV-1
GagPol gene products in the presence of Dox may result in negative selection of vector particle producing cell clones, we sought to
characterize the above cell clones’ stability. To this end, we cultured
the four cell clones in the presence of Dox and in the absence of
G418 for 4 weeks, after which production of vector particles was
induced by Dox withdrawal and addition of SB. As shown in Table 1,
all four cell clones exhibited kinetics and levels of vector particle
production comparable to the levels detected prior to four weeks
of cell culturing and expansion. These data indicate that the above
cell clones are potential precursors of IDLV stable producer cell lines.
Establishing the first IDLV producer cell lines via transduction with
conditional SIN vectors
Stable incorporation of vector genomes into packaging cells’ chromatin constitutes the last step in the process of establishing stable
vector producer cell lines. This step can be mediated either by transducing or by transfecting stable packaging cell lines, either with vector particles or with vector plasmid DNAs, respectively. Introducing
the vector cassettes by transduction is highly efficient and time
saving, and was employed successfully in the past to generate high
titer lentiviral and simple retroviral vector producer cell lines.60,67,68
Molecular Therapy — Methods & Clinical Development (2015) 15025
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Figure 3 Generating tetracycline-regulated integration-defective
lentiviral vector producer cell lines by transduction. (a) Depiction of the
cSIN vector pTK136. Note that the 3’U3 region is replaced by tetracyclineregulated element. (b) Vector production by the aforementioned vectorproducing cell lines (3-6-136, 3-8-136, 3-10-136, 3-12-136) was initiated
by Dox withdrawal from culture media. Sodium butyrate (5 mmol/l) was
added to culture media after 6 days of induction. Conditioned media
were collected at 2–4 days after addition of sodium butyrate. Viral titers
(IU/ml) were determined by scoring GFP expression by fluorescence
microscopy following serial dilution of conditioned media on 293T cells.

Since self-inactivating (SIN) vectors cannot be mobilized from transduced target cells, this approach cannot be employed as a means
to generate conventional SIN vector producing cell lines. This limitation was addressed by the development of the conditional-SIN
(cSIN) vectors, in which a tetracycline-regulated promoter replaced
the parental U3-enhancer/promoter sequences. Consequently, cSIN
vectors are efficiently mobilized from tTA expressing packaging cell
lines, yet retain their SIN features in all tTA-lacking target cells.62 We
sought to employ this technology to establish the first IDLV stable
producer cell lines and to further characterize the ability of the
© 2015 The American Society of Gene & Cell Therapy
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Table 2

Characterization of selected vTK1179 producer cell

lines
Clone No.

IUa/ml

P24gag (ng/ml)b

VCNc

3-8-1179 pool

1.1 ± 0.4 × 107

1,824 ± 445

13.9

3-12-1179 pool

1.6 ± 0.5 × 10

7

1,285 ± 443

58.9

3-8-1179-1

1.2 ± 0.3 × 10

8

2,801 ± 1,025

4.4

3-8-1179-2

2.8 ± 1.1 × 107

3,914 ± 1,275

2.7

3-12-1179-1

2.5 ± 0.2 × 10

7

2,024 ± 807

5.0

3-12-1179-2

2.6 ± 0.5 × 107

1,897 ± 699

7.6

3-12-1179-3

1.5 ± 0.3 × 107

1,296 ± 362

3-12-1179-4

3.4 ± 1.1 × 107

1,255 ± 261

3-12-1179-5

6

2.5 ± 0.9 × 10

1,698 ± 482

12.4

3-12-1179-6

2.6 ± 1.2 × 107

693 ± 116

2.3

3-12-1179-7

2.1 ± 1.0 × 10

1,853 ± 851

7

3-12-1179-8

4.3 ± 1.1 × 10

621 ± 146

3-12-1179-9

4.7 ± 1.1 × 107

885 ± 2

3-12-1179-10

7

1.8 ± 0.9 × 10

1,490 ± 306

3-12-1179-11

1.7 ± 0.5 × 106

852 ± 265

3-12-1179-12

6

5.6 ± 1.9 × 10

1,980 ± 423

3-12-1179-13

6.8 ± 0.6 × 106

1,581 ± 534

6

3-12-1179-14

N/A

629 ± 74

3-12-1179-15

2.6 ± 1.0 × 107

1,744 ± 522

3-12-1179-17

3.7 ± 0.9 × 106

810 ± 157

3-12-1179-18

6

9.0 ± 0.5 × 10

1,226 ± 168

3-12-1179-19

5.2 ± 0.4 × 107

1,861 ± 270

3-12-1179-20

2.8 ± 0.9 × 10

7

1,174 ± 181

3-12-1179-21

3.1 ± 0.4 × 107

1,153 ± 126

3-12-1179-22

7

7.5 ± 0.2 × 10

2,999 ± 109

3-12-1179-23

3.8 ± 0.8 × 107

938 ± 144

3-12-1179-24

2.8 ± 0.4 × 107

1,169 ± 210

3-12-1179-25

1.9 ± 1.9 × 107

640 ± 129

3-12-1179-26

2.2 ± 1.2 × 10

1,190 ± 570

3-12-1179-27

3.3 ± 0.9 × 10

2,722 ± 1,366

3-12-1179-28

4.0 ± 0.7 × 107

1,027 ± 13

3-12-1179-29

2.8 ± 0.2 × 10

1,458 ± 293

7
7

7

28.5
10.2

10.2

43.8

Vector production was initiated by Dox withdrawal. Sodium butyrate (5
mmol/l) was added to culture media after 6 days of induction. After 72 hours
in conditioned media, vector titers (IU/ml, a) were determined by scoring
GFP-positive cells following serial dilution on 293T cells. P24gag level (b) was
determined by ELISA. Numbers represent mean ± SD (n = 3). VCNs (viral copy
numbers, c) were measured by qPCR.

above four packaging cell lines (exhibiting the highest p24gag production) to generate high-titer IDLVs.
To this end, we transduced the four packaging cell lines with the
cSIN vector pTK136 (ref. 62) (Figures 1 and 3), from which the GFP
reporter gene is expressed under the control of a CMV promoter.
Heterogeneous pools of vector-transduced cell lines were induced
to generate vector particles by Dox withdrawal and addition of 5
mmol/l SB. Samples of conditioned media were collected between
© 2015 The American Society of Gene & Cell Therapy

days 2–4 post-SB addition and IDLV titers were determined by scoring GFP positive cells following serial dilution of conditioned media
on 293T cells. As shown in Figure 3b, between days 2 and 4 post-SB
exposure, the four novel IDLV producer cell lines generated vector titers higher than 106 IU/ml. However, IDLV titers (4–5 × 106 IU/
ml) generated by cell lines 3-8-136 and 3-12-136 were significantly
higher than the titers (1–1.5 × 106 IU/ml) obtained from clones
3-6-136 and 3-10-136. Altogether, these results support the notion
that cSIN vectors can rapidly and efficiently establish high titer IDLV
producing cell lines.
Establishing the first IDLV PPT-deleted producer cell lines by stable
transfection
Although time and labor consuming, stable transfection of plasmid vector DNA into stable packaging cells has been successfully
employed to establish stable producer cell lines generating high
titer SIN vectors.57–59,61 The fact that the efficiency of stable transfections is independent of the vector’s ability to successfully complete
its life cycle renders this methodology highly suitable for generating
stable producer cell lines of vectors unable to efficiently complete
reverse transcription and integration. These include PPT-deleted
vectors, which were developed as a means to further enhance vector biosafety by minimizing illegitimate, integrase-independent
integration of IDLVs.24 PPT-deleted vectors cannot efficiently complete reverse-transcription and thus generate minimal levels of
linear vector genomes. The majority of PPT-deleted vectors are in
the form of 1-LTR circles. Consequently, both integrase-mediated
integration of PPT-deleted ICLVs and illegitimate integration of PPTdeleted IDLVs are severely impaired.24 To combine the advantages
conferred by employing a stable vector producing cell line with the
enhanced biosafety properties of PPT-deleted vectors, we chose
to stably transfect a PPT-deleted vector into stable packaging cell
lines. Since both packaging cell lines (3–8 and 3–12) exhibited longterm Dox-dependent expression of GagPol and GFP/VSV-G, and
produced high titer cSIN IDLVs (Figures 2 and 3; Table 1), we chose
to base the establishment of the first stable PPT-deleted IDLV producer cell lines on the 3–8 and 3–12 packaging cells. To this end,
plasmid DNA comprising both the PPT-deleted vector pTK1179
cassette (expressing the GFP marker gene under the control of a
CMV promoter) and the Bleocin resistance gene encoding cassette
(Figures 1 and 4a) was transfected into the stable packaging cell lines
3–8 and 3–12.
Two heterogeneous 3–8 and 3–12 cell pools and 30 single
cell clones were isolated following Bleocin selection. Vector particle production from the above Bleocin resistant cell clones
was induced by withdrawal of Dox and addition of 5 mmol/l SB.
Concentration of p24gag and vector titers in conditioned media
samples collected at 72 hours post-SB treatment was determined
by ELISA and by scoring GFP expression following serial dilutions of conditioned media on 293T cells. As shown in Table 2,
both 3–8 and 3–12 cell pools generated comparable levels of
p24gag concentrations and high titers of the PPT-deleted IDLV
particles (1.1 ± 0.4 × 107 to1.6 ± 0.5 × 107 IU/ml). As expected, the
above isolated cell clones exhibited a wide range of vector titers,
which varied between 1.7 ± 0.5 × 106 IU/ml (clone 3-12-1179-11) to
1.2 ± 0.3 × 108 IU/ml (clone 3-8-1179-1). Note that one cell clone
(3-12-1179-14) failed to produce detectable levels of IDLVs (3-121179-14). The concentrations of p24gag in the above conditioned
media samples varied between 621 ± 146 ng/ml (clone 3-121179-8) and 3,914 ± 1,275 ng/ml (clone 3-8-1179-2). Although cell
lines producing low vector titers (<107 IU/ml) generated p24gag
Molecular Therapy — Methods & Clinical Development (2015) 15025
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Table 3

P24

gag

Stability of vector producer cell lines

ng/ml

12–136

—

—

Before
After

Titer IU/ml

8–136
a

8-1179-1

12-1179-22

2801 ± 1025

2999 ± 109

2374 ± 172

1047 ± 70

1716 ± 56

2952 ± 163

Before

4.0 ± 0.2 × 106

6.6 ± 1.2 × 106

1.2 ± 0.3 × 108

7.5 ± 0.2 × 107

After

5.7 ± 0.5 × 106

5.2 ± 0.4 × 106

1.1 ± 0.2 × 108

7.8 ± 0.3 × 107

b

945 IDLV

3-8-1179-1

3-12-136

b
945ICLV

a

3-12-1179-22

Production of integration-defective lentiviral vector’s by four packaging cell lines before (a) and after (b) five passages in culture (in the absence of G418) was
initiated by Dox withdrawal from culture media. Sodium butyrate (5 mmol/l) was added to culture media after 6 days of induction. After 72 hours in conditioned
media, vector particle concentration was determined by p24gag ELISA. Vector titers (IU/ml) were determined by scoring GFP-positive cells following serial dilution
on 293T cells. Numbers represent mean ± SD (n = 3).
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Figure 4 Generating stable producer cell lines by transfection. (a) Depiction of the PPT-deleted vector pTK1179. SVori: SV40 promoter and origin; Bleo:
Zeocin resistance gene; SVpA: SV40 polyadenylation signal; AmpR: Ampicillin resistance gene: (b) Western blot analysis of HIV-1 Gag (p55 and p24), Pol
(p66 and p51) and the VSV-G envelope protein in vector particles generated by either transient transfection (pTK945 integration-competent lentiviral
vectors and integration-defective lentiviral vector (IDLV)) and IDLV generated by the stable vector producer cell lines. Equal amounts of concentrated
virus (2 ng p24gag per lane for P24, 20 ng p24gag per lane for all other proteins) were loaded.

concentrations lower than 2,000 ng/ml, there was no direct correlation between p24gag concentrations and vector titers. To further
characterize the above vector producing cells, vector copy number per diploid host genome (VCN) was determined by qPCR in
the two cell pools and in 10 cell clones generating various vector
titers. Interestingly, notwithstanding the fact that both cell pools
produce comparable vector titers, the VCN in cell-pool 3-12-1179
was more than fourfold higher than the VCN in cell-pool 3-8-1179.
Similarly, VCN in the various cell clones was not correlated with
vector titers generated by these vector producing cell lines. To
characterize the above cell clones’ stability, we cultured the four
producer cell lines (8–136, 12–136, 8-1179-1, and 8-1179-22) in
the presence of Dox and in the absence of G418 for 5 weeks, after
which production of vector particles was induced by Dox withdrawal and addition of SB. As shown in Table 3, all four cell lines
exhibited levels of vector particle and infectious unit production
comparable to the levels detected prior to 5 weeks of cell culturing and expansion.
Efficient transduction of rodent CNS with stable producing cell
line-generated IDLVs
The establishment of a stable IDLV producing cell line was aimed at
facilitating large-scale IDLV production for in vivo applications. Thus,
we sought to characterize the efficacy of IDLVs generated by the
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above stable vector producing cell lines at transducing rat CNS. To
this end, IDLVs generated by cell clones 3-12-136, 3-12-1179-22 and
3-8-1179-1 were concentrated and purified by ultracentrifugation
as described by Kafri et al.60 Vector titers and concentration of p24gag
were determined by scoring GFP expression following serial dilution
on 293T cells and by p24gag ELISA, (3-12-1179-22: 2.70 × 1010 IU/ml,
p24gag 1.24 × 106 ng/ml; 3-8-1179-1: 3.34 × 1010 IU/ml, p24gag 1.59 × 106
ng/ml; 3-12-136, 1.28 × 109 IU/ml, p24gag 6.68 × 105 ng/ml, respectively). Western blot analysis of concentrated vector particles using
primary antibodies to HIV-1 p24gag and reverse-transcriptase proteins,
as well as the VSV-G envelope proteins, demonstrated efficient vector
particle formation and protein processing, which was comparable to
ICLV and IDLV particles generated by transient transfection (Figure 4).
PPT-deleted IDLVs (pTK1179) generated by the novel stable
producer cell line 3-8-1179-1 and conventional ICLV’s (pTK945)

generated by transient transfection were injected into the striatum
of 300–350 g male sprague dawley rats (total of 0.66 × 107 IU and
1.2 × 107 IU respectively). Transduction efficiency was determined at
week 5 postinjection by confocal microscopy. As shown in Figure 5, in
the rat striatum, ICLVs generated by transient transfection appeared
to support moderately greater overall transduction in comparison
to the cell line-generated PPT-deleted IDLVs (Figure 5a,b). These
findings are in line with the higher number of injected ICLV IU
and with an earlier study by Bayer et al.16 demonstrating reduced
© 2015 The American Society of Gene & Cell Therapy
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a

b

c

d

e

f

Figure 5 In vivo striatal transduction by integrating and nonintegrating
lentiviral vectors. Five weeks after bilateral 1 µl vector infusions, both the
nonintegrating (panel a) and the integrating (panel b) lentiviral vectors
transduced neurons in the rat striatum. The vast majority of transduced
cells were neurons that colocalized with NeuN (panel c, integrationcompetent lentiviral vectors (ICLV); panel d, integration-defective
lentiviral vector (IDLV); NeuN, red). Further example of this neuronal
tropism is illustrated in panel e where confocal microscopy showed
that glial fibrillary acidic protein (GFAP)-positive cells did not colocalize
with GFP for the ICLV (GFAP, red). In contrast, the ICLV, but not the IDLV,
transduced both oligodendrocytes and astrocytes (GFAP, red) in the
corpus callsosum dorsal to the striatum (panel f, arrows indicate G
 FPGFAP-positive cells). Panels a,b magnification bar = 250 µm; panels c–f,
magnification bars = 10 µm.

transgene expression from episomal lentiviral vectors. Also, we
observed that IDLV’s generated by a novel producer cell line efficiently transduced murine striatum (data not shown). Interestingly,
both ICLVs and IDLVs proved highly neurotrophic, such that almost
all of the GFP-positive cells colocalized with the neuronal marker
NeuN (Figure 5c,d). Furthermore, in the striatum virtually no GFPpositive cells exhibited colocalization with glial fibrillary acidic protein, a cellular marker of astrocytes (Figure 5e). However, a major
difference between the two vectors was observed in the corpus callosum dorsal to the striatum. The nonintegrating vector exhibited
little ability to transduce either oligodendrocytes or astrocytes in
the corpus callosum, while the integrating vector efficiently transduced both oligodendrocytes and astrocytes in the corpus callosum dorsal to the striatum (Figure 5f).

© 2015 The American Society of Gene & Cell Therapy

DISCUSSION
First stable IDLV packaging
IDLVs offer efficient gene delivery of large genetic cargos into
dividing and nondividing cells with minimal risk of insertional
mutagenesis (inherent in ICLVs). Increasingly, research groups
have been employing these vectors as a means to deliver marker
genes and therapeutic genetic cargos to a plethora of cell lines
and primary cells in vitro and to various target organs in vivo. The
successful IDLV-based gene replacement therapy in mouse models of retinal degeneration35 and hemophilia B36 underscore their
clinical potential. Furthermore, IDLVs have been used to transiently
express genome-editing enzymes in dividing cells.49 Indeed, Yi
et al.52 have recently conferred resistance to HIV-1 infection by
mutating the HIV-1 coreceptor CCR5 gene with IDLV-delivered
zinc-finger-nucleases.
To further facilitate the use of IDLV’s, we report here on the
establishment of the first stable IDLV cell lines. Titers of VSV-Gpseudotyped IDLVs generated by the novel cell lines were higher
than 108 and 1010 IU/ml prior to and after concentration, respectively, and are comparable to or higher than titers of most currently
used IDLVs and ICLVs generated by transient transfection.
Using the tetracycline inducible system, we circumvented the
difficulties associated with overexpressing the cytotoxic HIV-1
protease and the VSV-G envelope proteins. Importantly, the stable
packaging cell lines generated in this study exhibited stability and
maintained long-term, Dox-regulated expression of both the VSV-G
envelope and HIV-1 GagPol gene products.
Our strategy for establishing the IDLV producer cell lines focused
on minimizing the likelihood of emerging RCRs. Thus, all expression
cassettes comprising the novel packaging system were introduced
to the host genome separately using several independent rounds
of stable transfection/selection procedures (Figure 1). Although
time consuming, this approach minimizes the likelihood of
recombination-mediated RCR formation. Recent studies described
the use of gamma-retroviral vectors as a means to incorporate
the tetracycline-regulated trans-activator (tTA), envelope protein
expression cassettes and the HIV-1 packaging system to 293T as
a means to establish stable ICLV packaging cell lines.59,61 Although
efficient, this approach raises biosafety concerns associated with
mobilization of retroviral vectors carrying various components of
the HIV-1 vector producing system, as well as increased likelihood of
recombination-mediated RCR formation. These biosafety concerns
were underscored by a recent publication demonstrating low yet
detectable levels of lentiviral vector packaging of gamma-retroviral
genomes.69 The tight transcriptional regulation of the VSV-G envelope and the HIV-GagPol expression cassettes inhibits ongoing vector particle formation and consequently prevents superinfection of
the stable packaging cell line with VSV-G-pseudotyped particles.
This further reduces the likelihood of emerging RCRs.
In this study, we employed two different methodologies to introduce the vector cassette into the packaging cell line. In one approach,
we used cSIN vectors generated by transient transfection to transduce the newly developed integrase-deficient packaging cell lines.
This methodology is highly efficient and time saving. A pool of cSIN
vector-transduced packaging cells generated IDLV titers higher than
5 × 106 and 1 × 109 IU/ml prior to and after concentration. We predict
that screening and isolating highly efficient single cell clones could
further increase vector titers. The cSIN-based approach is optimal
for rapid establishment of stable producer cell lines, yet it is prem
ised on the ability of vectors generated by transient transfection
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to efficiently integrate into target cell genomes. Thus, it cannot be
employed to transfer integration-impaired vectors such as att sitesor PPT- deleted vectors24,29 to packaging cell lines. Stable transfection of vector DNA to packaging cells is the second methodology
described in this study for generating stable IDLV producing cell
lines. We employed this methodology (which is independent of the
vector’s integration efficiency) to incorporate PPT-deleted vectors
into packaging cell lines. Transfection of linearized (nonconcatemerized) vector plasmid DNA followed by Bleocin selection resulted in
the establishment of two stable heterogeneous vector-producing
cell pools. These exhibited vector titers higher than 107 IU/ml with
VCN’s of 14 and 59. As expected, 8 out of 30 isolated vector producing cell clones exhibited titers 2–10-fold higher (>108 IU/ml) than
the titers generated by the above cell pools. The lack of correlation
between p24gag concentration and VCN to vector titers suggests
that identification of highly efficient vector producing cell clones
cannot be based on these two parameters. The establishment of
the first PPT-deleted IDLV producer cell lines enhances the overall
biosafety of the IDLV system as it combines the advantage of minimal illegitimate integration conferred by PPT-deleted vectors with
the safety and efficiency gained by vector production by stable producer cell lines.
Overall, the establishment of stable PPT-deleted and conventional IDLV producing cell lines facilitates the usage and enhances
the safety of the IDLV system, rendering it more suitable for clinical
trials.
MATERIALS AND METHODS
Plasmids
The lentiviral vector pTK136, pTK1179, pTK945, and the packaging cassettes
ΔNRF (Int+), pTK939 (Int-) were generated, as described previously.24,62 The
inducible packaging system pTK1574 was derived by cloning a SacII/PvuI
fragment containing the tetracycline-regulated element and the human
CMV minimal promoter into similar sites in pTK939. The resultant pTK1574
expresses the integrase-deficient (D64E) HIV packaging cassette (excluding
the HIV-1 nef, vif, and vpr genes) under the control of a tetracycline regulated
promoter.

Cells
The inducible IDLV packaging system is based on the PVG3 cell line,58 in which
the synthetic trans-activator tTA is expressed under the control of a CMV promoter. In addition, PVG3 cells express the VSV-G envelope and the GFP marker
gene from a bidirectional tetracycline-inducible promoter. All cell types were
maintained in Dulbecco’s Modified Eagle Medium (DMEM)-High Glucose
(Thermo Scientific, Waltham, MA) supplemented with 10% fetal bovine
serum (FBS) (Atlantic Biologicals, Miami, FL), 100 U/ml penicillin, 100 µg/ml
streptomycin, and 250 ng/ml amphotericin B (Corning Cellgro, Manassas, VA).
The PVG3 cell line and all its derivatives were cultured on poly-lysine 0.001%
(Sigma, St Louis, MO) coated plates in the presence of 1 µg/ml Dox.

Viral vector production, concentration, and titration
Lentiviral vector production via three plasmids transient transfection was
performed as previously described.56,62 The following plasmid amounts were
used: 15 µg pTK945, 10 µg ΔNRF, and 5 µg of the VSV-G envelope plasmid
pMD.G. Vector producing cells were regularly maintained in 1 µg/ml Dox.
To induce vector production, cells were washed with phosphate-buffered
saline (PBS) for three times, and passaged onto poly-lysine precoated plates
in Dox-free medium. At 6 days post-Dox withdrawal, culture media were
supplemented with 5 mmol/l SB. Viral vectors containing media were collected at 60 hours after addition of SB.
For animal studies, viral vectors were concentrated by ultracentrifugation
as previously described.60 The emergence of RCRs was ruled out by three
independent safety assays (GFP rescue assay, Tat transfer assay, and Gag
transfer assay), as previously described.60
Titers were determined by scoring GFP expression following serial
dilutions on 293T cells. VCN was determined by multiplex PCR36 on the
Molecular Therapy — Methods & Clinical Development (2015) 15025

ABI7300 realtime PCR system. NotI794 primer/prober set (Left primer:
5′-taagaccaccgcacagca-3′; Right primer: 5′-cacttctccaattgtccctca-3′; Roche
Universal Probe Library #25, 4686993001, Indianapolis, IN) was used for
vectors detection, and paired with human GUSB primer/probe set (Roche
5190525001, Indianapolis, IN) as the reference gene.

HIV-1 p24 ELISA
Titers of physical vector particles were determined by p24gag ELISA using the
National Institutes of Health p24 Antigen Capture Assay kit, as previously
documented.18

Western blot
Cells and vector particles were lysed in RIPA buffer and characterized for
specific protein content by standard western blot analysis using denaturing
10% SDS–PAGE gels. Blots were probed with a murine anti-VSV-G monoclonal antibody (Ab) (1:1,000; P5D4, Santa Cruz, Dallas, TX), murine a nti-HIV-1
RT (1:200, 5B2B2; NIH AIDS Research & Reference Reagent Program,
Germantown, MD), and murine anti-HIV-1 p24 Gag (1:5,000, 6457; NIH AIDS
Research & Reference Reagent Program) followed by a polyclonal goat antimurine secondary Ab labeled with horseradish peroxidase (1:10,000; Pierce,
Grand Island, NY). Signals were detected by enhanced chemiluminescence
(ECL) reagent (GE Health Amersham, Pittsburgh, PA).

Experimental animals
All of the animals were pathogen-free male Sprague–Dawley rats obtained
from Charles Rivers. The animals were maintained in a 12-hour light–dark
cycle and had free access to food and water. All care and procedures were in
accordance with the Guide for the Care and Use of Laboratory Animals (DHHS
Publication No. (NIH) 85-23), and all procedures received prior approval by the
University of North Carolina Institutional Animal Care and Usage Committee.
For virus vector infusions, rats first were anesthetized with 50 mg/kg pentobarbital and placed into a stereotaxic frame. Subsequently, each rat received
a bilateral, striatal infusion (1 µl/side) of either the integrating (N = 3) or the
nonintegrating (N = 3) lentiviral vector using a 32-gauge stainless steel injector and a Sage infusion pump (interaural line (IAL) 10.0 mm, lateral 3.0 mm,
vertical 5.5 mm, according to the atlas of Paxinos and Watson, 1985). The 1 µl
infusion occurred over a period of 5 minutes, and the injector was left in place
for 3 minutes postinfusion to allow diffusion.

Immunohistochemistry
Five weeks after the vector infusions, the rats received an overdose of pentobarbital (100 mg/kg pentobarbital, i.p.) and subsequently were perfused
transcardially with ice-cold 0.1M sodium PBS (pH = 7.4), followed by 4%
paraformaldehyde in 0.1M phosphate buffer (pH = 7.4). After overnight fixation in the paraformaldehyde-phosphate buffer, vibratome sections (40 µm
thick) were taken and rinsed in PBS. Tissue sections were incubated in 10%
normal goat serum and 0.1% Triton X-100 in PBS for 30 minutes. Next, sections were incubated with a primary antibody to NeuN (1:1,000, Chemicon,
Pittsburgh, PA) or glial fibrillary acidic protein (1:4,000, DAKO A/S, Glostrup,
Denmark) overnight in 3% normal goat serum, 0.2% Triton X-100 and PBS.
Tissue sections were then rinsed in PBS, incubated in blocking serum (10%
normal goat serum, 0.1% Triton X-100, PBS) for 1 hour and then incubated
with a secondary fluorescent antibody (Alexa-fluor 594 goat anti-rabbit, or
goat-anti-mouse, Molecular Probes) for 1 hour at 4 °C. Following three rinses
in PBS, the sections were mounted on slides and coverslipped with fluorescent mounting media. The eGFP and Alexa-fluor 594 fluorescence were
visualized on either an Olympus IX 70 fluorescence microscope or a Leica
SP2 laser scanning confocal microscope. All cases of colocalization were
determined using the confocal microscope and the presence of colocalization within a Z-stack.
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